US Broker Ratings

Maravai LifeSciences Holdings (MRVI): Investor Outlook Reveals 6.47% Potential Upside Amidst Challenging Metrics

Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI) is a key player in the burgeoning biotechnology sector, with a market capitalization of $1.35 billion. Based in San Diego,..

LENZ Therapeutics, Inc. (LENZ): Investor Outlook on a Biotech Stock with 196.11% Potential Upside

LENZ Therapeutics, Inc. (NASDAQ: LENZ) is capturing investor attention with its ambitious vision-focused biopharmaceutical pipeline and a staggering potential upside of 196.11%, according to analyst targets...

Immunome, Inc. (IMNM) Stock Analysis: A Promising Upside of Nearly 51% as Analysts Show Strong Support

Immunome, Inc. (NASDAQ: IMNM) is capturing the attention of investors with a compelling story in the biotechnology sector. Based in Bothell, Washington, this clinical-stage biotech company..

Dianthus Therapeutics, Inc. (DNTH) Stock Analysis: A Biotech Gem with 47.93% Potential Upside

Dianthus Therapeutics, Inc. (NASDAQ: DNTH) has emerged as a compelling investment opportunity within the biotechnology sector, bolstered by a market capitalization of $1.89 billion and significant..

Owens & Minor, Inc. (OMI) Stock Analysis: Exploring the 94% Potential Upside in Healthcare Distribution

Owens & Minor, Inc. (OMI), a key player in the healthcare sector, specifically in medical distribution, presents an intriguing opportunity for investors. Despite facing challenges, the..

Cogent Biosciences, Inc. (COGT): Investor Outlook on a Biotech Innovator with a 28% Upside Potential

For investors with a keen eye on the biotechnology sector, Cogent Biosciences, Inc. (NASDAQ: COGT) presents an intriguing opportunity marked by significant growth potential. Headquartered in..

Neuropace, Inc. (NPCE) Stock Analysis: Exploring a 10.95% Potential Upside with Strong Buy Ratings

Investors with a keen eye on the healthcare sector, specifically in the realm of medical devices, may find Neuropace, Inc. (NASDAQ: NPCE) a compelling opportunity. With..

Akebia Therapeutics, Inc. (AKBA) Stock Analysis: Unveiling a Remarkable 302.99% Potential Upside

Akebia Therapeutics, Inc. (NASDAQ: AKBA) has captured the attention of investors with its notable potential upside of 302.99%. This biopharmaceutical company, focused on kidney disease therapeutics,..

Praxis Precision Medicines, Inc (PRAX) Stock Analysis: Navigating the 55% Potential Upside in Biotech

Praxis Precision Medicines, Inc (NASDAQ: PRAX) is capturing investor attention with its promise of substantial growth in the biotechnology sector. With a focus on central nervous..

Pharvaris N.V. (PHVS) Stock Analysis: A 78.62% Potential Upside and Strong Buy Ratings

For investors with a keen interest in biotechnology, Pharvaris N.V. (PHVS) presents a compelling opportunity with strong growth potential. Listed in the healthcare sector under the..

Immatics N.V. (IMTX) Stock Analysis: A Deep Dive into its 92.79% Potential Upside

Investors interested in the biotechnology sector should turn their attention to Immatics N.V. (NASDAQ: IMTX), a clinical-stage biopharmaceutical company specializing in cutting-edge cancer immunotherapies. Headquartered in..

Avadel Pharmaceuticals (AVDL) Investor Outlook: Navigating a 54.90% Revenue Growth Amidst a Hold-Heavy Consensus

Avadel Pharmaceuticals plc (NASDAQ: AVDL), a biopharmaceutical company based in Dublin, Ireland, is carving out a niche in the healthcare sector, specifically within the drug manufacturing..

Bicycle Therapeutics plc (BCYC) Stock Analysis: Unpacking a 232% Potential Upside

Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company based in Cambridge, UK, is drawing significant attention in the healthcare sector. With a market capitalization of $448.81..

Zymeworks Inc. (ZYME): Analyzing the 50% Upside Potential in Biotech Innovator

Zymeworks Inc. (NASDAQ: ZYME) is making waves in the biotech sector with a notable potential upside of 50.72%, attracting significant interest from investors seeking opportunities in..

iRadimed Corporation (IRMD) Stock Analysis: Navigating Healthcare’s Pinnacle with a 23.31% ROE

iRadimed Corporation (NASDAQ: IRMD), a standout player in the healthcare sector’s medical devices industry, is capturing attention with its impressive financial metrics and strategic positioning. Headquartered..

Day One Biopharmaceuticals, Inc (DAWN) Stock Analysis: High Potential Upside with a 124% Growth Prospect

Day One Biopharmaceuticals, Inc. (NASDAQ: DAWN), a commercial-stage biotechnology company, is garnering attention with its ambitious focus on developing treatments for both childhood and adult diseases...

Arcus Biosciences, Inc. (RCUS): Analyst Consensus Reveals a 51.45% Potential Upside for Biotech Investors

Arcus Biosciences, Inc. (RCUS), a clinical-stage biopharmaceutical company based in Hayward, California, is making waves in the biotechnology sector with its innovative cancer therapies. With a..

Trevi Therapeutics, Inc. (TRVI) Stock Analysis: Exploring a Nearly 98% Upside Potential

Trevi Therapeutics, Inc. (NASDAQ: TRVI) is capturing investor attention in the biotechnology sector due to its compelling growth prospects and a substantial upside potential. As a..

Vir Biotechnology, Inc. (VIR) Stock Analysis: Potential 175.99% Upside and Strong Buy Ratings Signal Investor Opportunity

Vir Biotechnology, Inc. (NASDAQ: VIR), a clinical-stage biopharmaceutical company, is catching investor attention with its promising 175.99% potential upside and unanimous buy ratings. With a focus..

HealthStream, Inc. (HSTM) Stock Analysis: Exploring a 47% Potential Upside with Robust SaaS Solutions

HealthStream, Inc. (NASDAQ: HSTM), a prominent player in the health information services sector, offers a compelling investment narrative for those interested in the burgeoning intersection of..

US Broker Ratings

US Broker Ratings

FTSE 100

Funds